Ke ʻimi nei ʻo Pfizer i ka mana hoʻohana pilikia mai ka FDA no kāna moʻolelo Covid-19 antiviral pill Paxlovid.
Māhele ʻatikala
Ma nā kuʻekuʻe wāwae o Merck antiviral molnupiravir's UK ʻae ʻia, ua hoʻomaka ʻo Pfizer e kiʻi i kāna ponoʻī Covid-19, ʻo Paxlovid, ma ka mākeke.I kēia pule, ua ʻimi ka mea hana lāʻau lapaʻau US i ka ʻae ʻana mai ka US Food and Drug Administration (FDA) no kāna moho antiviral novel i nā poʻe me Covid-19 haʻahaʻa a me ka haʻahaʻa, ʻoi aku ka nui o ka pilikia o ka hoʻokipa a i ʻole ka make. hoʻomaka i ke kaʻina hana no ka ʻimi ʻana i ka ʻae kānāwai ma nā ʻāina ʻē aʻe e like me UK, Australia, New Zealand a me South Korea, a hoʻolālā e waiho i nā noi hou. Pehea e hana ai ʻo Paxlovid? ritonavir, he lāʻau antiretroviral i hoʻohana mau ʻia e mālama i ka maʻi HIV.Hoʻopilikia ka mālama ʻana i ka hana hou ʻana o SARS-CoV-2 i loko o ke kino ma o ka hoʻopaʻa ʻana i ka protease like me 3CL, kahi enzyme koʻikoʻi i ka hana a me ka hana hou ʻana o ka maʻi.
Wahi a kahi loiloi interim, ua hōʻemi ʻo Paxlovid i ka pilikia o ka hale hoʻokipa e pili ana iā Covid-19 a i ʻole ka make e 89% i ka poʻe i loaʻa i ka mālama ʻana i loko o ʻekolu mau lā o ka hoʻomaka ʻana o ka hōʻailona.Ua ʻike maikaʻi ʻia ka lāʻau lapaʻau - ʻo 1% wale nō o nā maʻi i loaʻa iā Paxlovid i hoʻopaʻa ʻia i ka haukapila a hiki i ka lā 28 i hoʻohālikelike ʻia me 6.7% o ka poʻe i komo i kahi placebo-ua hoʻopau koke ʻia kāna hoʻokolokolo Phase II/III a ua waiho ʻia ka hoʻouna ʻana i nā kānāwai i ka FDA ma mua o i manaoia.Eia kekahi, ʻoiai he 10 mau make i hōʻike ʻia ma ka lima placebo, ʻaʻohe mea i loaʻa ma waena o nā poʻe i loaʻa iā Paxlovid.E like me ka molnupiravir, lawelawe ʻia ʻo Paxlovid ma ka waha, ʻo ia ka mea hiki i nā mea maʻi Covid-19 ke lawe i ka lāʻau lapaʻau ma ka home i ka wā mua o ka maʻi.ʻO ka manaʻolana ʻo nā antivirals hou e like me nā mea mai Merck a me Pfizer e ʻae i ka poʻe me nā maʻi maʻalahi a i ʻole nā maʻi o ka coronavirus e mālama koke ʻia, e pale ana i ka piʻi ʻana o ka maʻi a kōkua i ka pale ʻana i nā haukapila mai ka hoʻoluhi ʻia.
ʻO ka hoʻokūkū lāʻau Covid-19 ʻO Merck's molnupiravir, ka pilo mua i ʻae ʻia no Covid-19, ua manaʻo ʻia he mea hiki ke hoʻololi i ka pāʻani mai ka wā i ʻike ʻia ai ua hōʻemi ʻia ka hoʻokipa a me ka make ma kahi o 50%.Akā ʻaʻole ia he manaʻo ʻaʻole e loaʻa ka makana antiviral a Pfizer i ka mākeke.Ke hoʻohiki nei ka loiloi manawa o ka pono o ka molnupiravir, akā ʻo ka hōʻemi nui o ka pilikia i hōʻike ʻia e Pfizer e hōʻike ana i kāna pila e hiki ke hōʻoia i kahi mea kaua waiwai i loko o nā mea kaua o ke aupuni e kūʻē i ka maʻi maʻi. hoʻopaʻapaʻa antiviral.Ua hōʻike aku kekahi poʻe loea i nā hopohopo e pili ana i ka hana ʻana o ka molnupiravir e kūʻē iā Covid-19 - ka hoʻohālikelike ʻana i nā molekele RNA e hoʻowalewale i nā mutations viral - hiki ke hoʻolauna i nā mutations pōʻino i loko o ke kanaka DNA.ʻO Paxlovid, kahi ʻano antiviral ʻē aʻe i ʻike ʻia he inhibitor protease, ʻaʻole i hōʻike i nā hōʻailona o "mutagenic DNA interactions", i ʻōlelo ai ʻo Pfizer.
Ka manawa hoʻouna: Nov-19-2021